Bulletin du Cancer, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Current Oncology Reports, Journal Year: 2025, Volume and Issue: unknown
Published: March 8, 2025
Abstract Purpose of Review Cutaneous T-Cell Lymphoma (CTCL) poses challenges both in diagnosis and prognosis. The purpose this review is to address the role profiling immune non-immune cells tumor microenvironment (TME) as it provides information for better diagnosis, prognosis, biomarker discovery, personalized treatment strategies. Recent Findings evidence suggests that progression CTCL closely linked Tumor Microenvironment which comprises various cell types including cells, stromal blood vessels, extracellular matrix. Cell within TME demonstrates perplexity intracellular communication different fates their mediators disease progresses. Summary a rare form non-Hodgkin lymphoma often misdiagnosed due its similarity other skin conditions. It encompasses diseases like Mycosis fungoides (MF) Sézary Syndrome (SS), with latter being more severe. Advances studying have shown pivotal progression, highlighting need comprehensive enhance personalization.
Language: Английский
Citations
0
Journal of Skin Cancer, Journal Year: 2025, Volume and Issue: 2025(1)
Published: Jan. 1, 2025
Cutaneous T-cell lymphomas (CTCLs) are a type of non-Hodgkin lymphoma that usually involves the skin. It has different subtypes including mycosis fungoides (MFs), Sézary syndrome (SS), primary cutaneous anaplastic large (PC-ALCL), lymphomatoid papulosis (LyP), and subcutaneous panniculitis-like (SPTCL). There several reports incidence, relapse, or progression CTCLs by using specific drugs. We aim to identify drug- vaccine-induced CTCL characteristics. A systematic search was conducted MeSH terms/keywords: drug-induced drug-associated vaccine-associated vaccine induced through PubMed/Medline, Scopus, Web Science, Embase until May 10, 2024. Out 14,031 papers, 60 articles were included, involving 71 patients with mean age 53.5 ± 17 years. Among them, 52.1% male. Medications categorized into four groups: conventional, biologics, small molecules, vaccines. The most frequently reported medications in first group fingolimod (n = 8) methotrexate 7). Infliximab 6) etanercept 5) commonly biologics. Pfizer-BioNTech 11) JAK inhibitors 3) molecules. LyP 17) CTCL, followed PC-ALCL 13), MF 11), SS 8), SPTCL 8). common underlying conditions rheumatoid arthritis 15) multiple sclerosis 10). Twenty (28%) experienced disease regression after discontinuing drug, SD 8.6 8.8 weeks. In 14 (20%), chemotherapy and/or radiotherapy initiated. Six passed away being diagnosed CTCL: two because recurrence other complications. is important recognizing as possible, although rare, adverse effect certain drugs vaccines, taking history vaccinations, especially COVID-19 immunosuppressive such fingolimod, TNF-a inhibitors, methotrexate.
Language: Английский
Citations
0
Published: June 3, 2024
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of characterised by high relapse rates and no curative treatments unless the allogeneic stem cell transplantation. The main complication in management this kind malignancy is variability that characterises genetic clinical features among CTCL subtypes. JAK/STAT, MAPK/ERK, PI3K/Akt, NF-kB those signalling pathways found altered responsible for promoting both pro-tumorigenic microenvironment. Thus, targeting key players these can be an advantageous therapeutic option CTCL. In review, we aim to summarise different approaches precisely inhibit kinases each cited signalling. JAK inhibitors seem most promising kinase However, adverse events have been reported especially patients with immunosuppression or underlying autoimmune disease. More studies needed, trials, investigate benefits drugs treatment cutaneous lymphomas.
Language: Английский
Citations
1
JAAD Case Reports, Journal Year: 2024, Volume and Issue: 52, P. 88 - 90
Published: Aug. 17, 2024
Language: Английский
Citations
1
Kinases and Phosphatases, Journal Year: 2024, Volume and Issue: 2(3), P. 255 - 267
Published: Aug. 28, 2024
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of characterised by high relapse rates and no curative treatments unless the allogeneic stem cell transplantation. The main complication in management this kind malignancy is variability that characterises genetic clinical features among CTCL subtypes. JAK/STAT, MAPK/ERK, PI3K/Akt, NF-kB those signalling pathways found altered responsible for promoting both pro-tumorigenic microenvironment. Thus, targeting key players these can be an advantageous therapeutic option CTCL. In review, we aim to summarise different approaches precisely inhibit kinases each cited signalling. JAK inhibitors seem most promising kinase However, adverse events have been reported especially patients with immunosuppression or underlying autoimmune disease. More studies needed, trials, investigate benefits drugs treatment cutaneous lymphomas.
Language: Английский
Citations
1
International Journal of Dermatology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 9, 2024
Language: Английский
Citations
1
JAMA Dermatology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 11, 2024
This case report describes 2 older patients with refractory mogamulizumab-associated rash successfully treated upadacitinib.
Language: Английский
Citations
1
British Journal of Dermatology, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 12, 2024
Abstract Background Mycosis fungoides (MF) usually has an indolent course. However, some patients develop more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest unfavourable prognosis. Objectives To describe the clinicopathological characteristics value pMF. Methods We retrospectively collected data from all with histological pustules diagnosed 2009 to 2020. The outcomes pMF at diagnosis (pMFD) were compared those a cohort nonpustular (NpMF). Results Thirty-three (including 22 pMFD) 86 NpMF included. Median age was 61 years [interquartile range (IQR) 50–75]. median duration follow-up for pMFD 32 months (IQR 14–49). Clinically, 33% had pustules. Large cell transformation (LCT) occurred in 17 patients. Patients significantly advanced-stage showed LCT than [50% vs. 7% (P < 0.001) 23% 0% 0.001), respectively]. On multivariate Cox analysis, presence associated shorter overall survival (OS) [hazard ratio (HR) 13.90, 95% confidence interval (CI) 2.40–79.00); P = 0.003] early-stage (HR 11.09, CI 1.56–78.82; 0.02). In Fine Gray model higher cumulative incidence (subdistribution HR 2.43–79.00; 0.003) OS after occurrence during 37 months, 5-year rate 25% (95% 0.06–0.50). Conclusions often follows course, high risk survival, even disease. Histological might represent independent poor factor, be confirmed by further studies. As are not always identified clinically, found on histology should mentioned pathology reports prompt discussion closer follow-up.
Language: Английский
Citations
0
Bulletin du Cancer, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Citations
0